Hyderabad, India
Bharat Biotech, founded in 1996 by Dr. Krishna M. Ella and Mrs. Suchitra K. Ella, is a prominent player in the biotechnology sector, focused on the manufacture of vaccines and bio-therapeutics from their headquarters in India. Known for their pioneering work in biotechnology, their mission is to provide affordable, safe, and high-quality solutions that address major health concerns, especially in emerging markets.
Over the years, Bharat Biotech has made investments in R&D to drive innovation, resulting in significant breakthroughs. Their portfolio includes the world’s first eco-friendly recombinant Hepatitis-B vaccine and the clinically proven Typbar TCV®, a conjugate Typhoid vaccine. Additionally, ROTAVAC® and ROTAVAC 5D® emphasize their expertise in producing groundbreaking vaccines.
Their transparency and commitment to integrity in clinical trials are well-regarded, alongside their comprehensive data integrity procedures. Recently, Bharat Biotech attracted a $14.10M grant investment on 01 June 2020 from the Coalition for Epidemic Preparedness Innovations, underlining their industry standing and potential for future growth and contribution to global health.
